About Mas-related G-protein coupled receptor member E
Mas-related G-protein coupled receptor member E (MRGPRE) is a protein
from Homo sapiens identified by UniProt accession
Q86SM8, 312 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Mas-related G-protein coupled receptor member E |
|---|
| UniProt accession | Q86SM8 |
|---|
| Gene | MRGPRE |
|---|
| Organism | Homo sapiens |
|---|
| Length | 312 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (24)
Diseases linked to this target (Open Targets).
- migraine disorder · score 0.39
- metabolite measurement · score 0.07
- pentosuria · score 0.06
- uridine-cytidineuria · score 0.06
- isolated sedoheptulokinase deficiency · score 0.06
- Idiopathic hypercalciuria · score 0.06
- medullary sponge kidney · score 0.04
- Dent disease · score 0.04
- congenital lipoid adrenal hyperplasia due to STAR deficency · score 0.04
- tumoral calcinosis, hyperphosphatemic, familial, 2 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86SM8-F1 | alphafold | PREDICTED | 85.22 | — |
Amino-acid sequence (312 residues)
MMEPREAGQH VGAANGAQED VAFNLIILSL TEGLGLGGLL GNGAVLWLLS SNVYRNPFAI YLLDVACADL IFLGCHMVAI VPDLLQGRLD FPGFVQTSLA TLRFFCYIVG LSLLAAVSVE QCLAALFPAW YSCRRPRHLT TCVCALTWAL CLLLHLLLSG ACTQFFGEPS RHLCRTLWLV AAVLLALLCC TMCGASLMLL LRVERGPQRP PPRGFPGLIL LTVLLFLFCG LPFGIYWLSR NLLWYIPHYF YHFSFLMAAV HCAAKPVVYF CLGSAQGRRL PLRLVLQRAL GDEAELGAVR ETSRRGLVDI AA
Explore Mas-related G-protein coupled receptor member E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets